Alzamend Neuro’s (ALZN) “Sell (E+)” Rating Reaffirmed at Weiss Ratings

Weiss Ratings restated their sell (e+) rating on shares of Alzamend Neuro (NASDAQ:ALZN) in a research note issued to investors on Tuesday,Weiss Ratings reports.

ALZN has been the topic of several other reports. Ascendiant Capital Markets decreased their target price on shares of Alzamend Neuro from $45.00 to $42.00 and set a “buy” rating on the stock in a research note on Thursday, September 25th. Wall Street Zen downgraded shares of Alzamend Neuro from a “hold” rating to a “sell” rating in a research note on Saturday, August 9th. One analyst has rated the stock with a Buy rating and one has issued a Sell rating to the company. Based on data from MarketBeat.com, Alzamend Neuro has a consensus rating of “Hold” and a consensus price target of $42.00.

Alzamend Neuro Stock Up 1.8%

Shares of NASDAQ ALZN opened at $2.24 on Tuesday. Alzamend Neuro has a 52 week low of $2.06 and a 52 week high of $17.10. The firm’s fifty day moving average is $2.39 and its 200 day moving average is $3.75.

Insider Activity

In related news, Director Milton C. Ault III sold 101,394 shares of the business’s stock in a transaction dated Wednesday, October 8th. The shares were sold at an average price of $2.44, for a total transaction of $247,401.36. Following the transaction, the director owned 28,657 shares in the company, valued at $69,923.08. The trade was a 77.96% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Insiders have sold a total of 904,632 shares of company stock worth $2,211,980 in the last 90 days. 30.21% of the stock is owned by insiders.

Alzamend Neuro Company Profile

Alzamend Neuro, Inc, an early clinical-stage biopharmaceutical company, focuses on developing various products for the treatment of neurodegenerative and psychiatric disorders. The company's pipeline includes AL001, which delivers a therapeutic combination of lithium, proline, and salicylate for the treatment of Alzheimer's, bi-polar disorder, post-traumatic stress disorder, major depressive disorder, other neurodegenerative diseases, and psychiatric disorders; and ALZN002 stage, which uses a method using a mutant-peptide sensitized cell as a cell-based therapeutic vaccine to restore the ability of a patient's immunological system to combat Alzheimer's disease.